Peripheral Neuropathy News and Research

RSS
Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
Study: Gene variant linked to increased risk of vincristine-induced peripheral neuropathy in children

Study: Gene variant linked to increased risk of vincristine-induced peripheral neuropathy in children

Researchers identify first genetic variation linked to increased risk of peripheral neuropathy

Researchers identify first genetic variation linked to increased risk of peripheral neuropathy

Advances in stem cell therapy can improve outcomes for patients with chronic diabetic foot ulcers

Advances in stem cell therapy can improve outcomes for patients with chronic diabetic foot ulcers

Research findings may point to new treatment for patients with Mitofusin 2 deficiency

Research findings may point to new treatment for patients with Mitofusin 2 deficiency

Scientists identify first genetic marker linked to severe neurological toxicity

Scientists identify first genetic marker linked to severe neurological toxicity

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

Drug combination shows promise in patients with newly diagnosed multiple myeloma

Drug combination shows promise in patients with newly diagnosed multiple myeloma

Dr. Grace Campbell receives RNF Fellow Research Grant Award

Dr. Grace Campbell receives RNF Fellow Research Grant Award

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Regular participation in physical activity may help reduce weight and treat diabetes

Regular participation in physical activity may help reduce weight and treat diabetes

Loss of sensation in the feet of diabetics may predict heart attack, stroke

Loss of sensation in the feet of diabetics may predict heart attack, stroke

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

NeuroMetrix receives marketing certification from TÜV SÜD Japan for NC-stat DPNCheck

NeuroMetrix receives marketing certification from TÜV SÜD Japan for NC-stat DPNCheck

SLU researchers discover pain pathway and potential way to block it

SLU researchers discover pain pathway and potential way to block it

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

NeuroMetrix announces marketing launch of NC-Stat DPNCheck in Japan

NeuroMetrix announces marketing launch of NC-Stat DPNCheck in Japan

Corneal nerve fiber assessment has potential to monitor peripheral neuropathy induced by HIV

Corneal nerve fiber assessment has potential to monitor peripheral neuropathy induced by HIV

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease